Your AI-Trained Oncology Knowledge Connection!
Patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, appeared to be effective at the recommended expansion dose of 5.6 mg/kg in patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer based on clinically meaningful antitumor activity and a manageable safety profile.
Patients with extensive-stage small cell lung cancer show greater response when atezolizumab is added to carboplatin and etoposide versus placebo in the IMpower133 trial.
When also considering age and Rai score, the effect of Charlson comorbidity index score on mortality was found to be statistically nonsignificant for patients with chronic lymphocytic leukemia, although higher scores were associated with worse overall and relative survival.
Based on results of the VISION study, the FDA has granted accelerated approval to tepotinib for MET exon 14 skipping altered metastatic non–small cell lung cancer.
Investigators suggested that findings across different clinics can help inform future implementation of the Colorectal Cancer Control Program (CRCCP).
The hospitalist at Memorial Sloan Kettering Cancer Center highlighted important takeaways from a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.
According to trial investigators, the results of the ongoing BFBC008 study point support the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory non–small cell lung cancer.
The urologist at Dana-Farber Cancer Institute/Brigham and Women’s Cancer Center spoke about the impact of a decline in cancer screening tests being performed during the first wave of the pandemic.
According to the study authors, an end-to-end deep learning approach to generate CT-based biomarkers may help produce more rapid clinical translation.
Data from this international study further developed the field of head and neck cancers, elaborating on contributions from key cancer-associated genes, proteins, and signaling pathways.
CancerNetwork®’s podcast features Justin Gregg, MD, lead author of a study investigating the Mediterranean diet and how it impacts men with localized prostate cancer.
The MET inhibitor tepotinib demonstrated durable clinical activity in non‒small cell lung cancer tumors harboring MET exon 14 skipping mutations.
Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.
“Preliminary TRIDENT-1 data are very encouraging and support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC,” according to Byoung Chul Cho, MD, PhD.
To evaluate the association between radiation facility case volume and OS among men with lymph node–positive prostate cancer who receive external beam radiation therapy, this cohort study assessed men diagnosed with T1N1M0 to T4N1M0 disease treated with curative-intent radiotherapy and androgen deprivation therapy.
Savolitinib plus osimertinib overcomes treatment resistance in non–small cell lung cancer with oncogenic driver mutations.
The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
Based on the results of an analysis, investigators suggested that if high-dose daunorubicin and cytarabine is the selected consolidation treatment for younger patients with acute myeloid leukemia, a fourth course of therapy is likely beneficial for most.
The phase 3 NeoADAURA trial will examine both single-agent osimertinib as well as the combination with platinum-based chemotherapy versus chemotherapy alone in the neoadjuvant setting in patients with resectable, stage II to IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.
Multiple key efficacy end points continue to favor atezolizumab versus chemotherapy for patients with PD-L1–high, wild-type nonsquamous or squamous non–small cell lung cancer in the first line, according to a phase 3 trial follow-up.
The investigational TROP-2–directed antibody-drug conjugate datopotamab deruxtecan will move forward in the treatment of relapsed/refractory non–small cell lung cancer, according to results from the 2020 World Conference on Lung Cancer Singapore.
Safety and antitumor activity of mobocertinib became evident after results of a trial involving EGFR exon 20 insertion–mutant non–small cell lung cancer were reported at the 2020 World Conference on Lung Cancer Singapore.
Liposomal irinotecan as second-line therapy for SCLC is feasible, safe after frontline platinum therapy failure.
Patients with KRAS G12C–mutated advanced non–small cell lung cancer show antitumor response and survival benefit with the KRAS G12C inhibitor sotorasib, formerly AMG 510.
Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.
Bellicum Pharmaceuticals, the developer of BPX-601, can now begin enrolling patients to their phase 1/2 trial again without modification to the study protocol.
Data presented at the 2020 World Conference on Lung Cancer Singapore reported gains in survival at the population and patient levels for those with SCLC treated with immunotherapy.
Results from the phase 3 ADAURA trial found extended disease-free survival for patients, irrespective of previous adjuvant chemotherapy received or disease stage.
A Japanese study supports the use of nab-paclitaxel for previously treated non–small cell lung cancer based on noninferiority end points being met.
